Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD38-SADA
- Development stage
- Unknown
- Lead developer
- Y-mAbs Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
CD38-SADA is a bispecific recombinant fusion protein designed as a pre-targeted radioimmunotherapy (PRIT) agent for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL). It utilizes Y-mAbs Therapeutics' proprietary Self-Assembling and Disassembling Antibody (SADA) technology platform, which enables a two-step therapeutic approach. In the first step, non-radiolabeled tetrameric forms of the protein are administered and bind with high avidity to the tumor-expressed antigen, lymphocyte differentiation antigen CD38. Unbound proteins disassemble into monomers that are rapidly cleared by renal excretion. In the second step, a radioactive payload—typically Lutetium 177-DOTA—is infused and binds specifically to tumor-localized antibody constructs for targeted irradiation of cancer cells while minimizing off-target toxicity. The construct was developed using technology licensed from Memorial Sloan Kettering Cancer Center and MIT[1][2][4][5][6][7][9].
- Other names
- CD38-SADACD-38-SADACD 38-SADACD38 SADACD-38 SADACD 38 SADACD38SADACD-38SADACD 38SADA
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on CD38-SADA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD38-SADA.